We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
ClinicalTrials.gov Menu

Dose-Ranging Study for Prolonged Postoperative Analgesia in Subject Undergoing Total Knee Arthroplasty (TKA)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00485693
Recruitment Status : Completed
First Posted : June 13, 2007
Results First Posted : August 6, 2013
Last Update Posted : June 28, 2022
Information provided by (Responsible Party):
Pacira Pharmaceuticals, Inc

Brief Summary:
Dose-ranging study for prolonged postoperative analgesia in subjects undergoing total knee arthroplasty

Condition or disease Intervention/treatment Phase
Postoperative Pain Drug: Bupivacaine HCl Drug: SKY0402 Phase 2

Detailed Description:
This is a phase 2, multicenter, parallel-group, active-control, randomized, double-blind, dose-ranging study conducted to evaluate three dose levels of SKY0402 compared with 150 mg of bupivacaine HCl.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 138 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
Official Title: A Phase 2 Multicenter, Randomized, Double-blind, Parallel-group, Active-control, Dose-ranging Study to Evaluate the Safety, Efficacy, and Comparative Systemic Bioavailability of a Single Administration of SKY0402 Via Local Infiltration for Prolonged Postoperative Analgesia in Subjects Undergoing Total Knee Arthroplasty.
Study Start Date : June 2007
Actual Primary Completion Date : August 2009
Actual Study Completion Date : August 2009

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Active Comparator: Bupivacaine HCl
Bupivacaine HCl (Marcaine 0.25% with epinephrine 1:200,000)
Drug: Bupivacaine HCl
150 mg Bupivacaine HCl
Other Name: Bupivacaine HCl (Marcaine 0.25% with epinephrine 1:200,000)

SKY0402 at various dosage levels. Single administration.
Drug: SKY0402
600 mg SKY0402 (study drug)
Other Name: EXPAREL

Primary Outcome Measures :
  1. Area Under the Curve (AUC) of the Numeric Rating Scale (NRS) With Activity (NRS-A) Pain Intensity Scores Through Postoperative Day 4 [ Time Frame: 0 to 96 hours ]
    The subject's pain intensity was to be assessed with activity (NRS-A) after actively flexing the involved knee to the maximum flexion point possible. The subject was asked to respond to the following question: "On a scale of 0 to 10, where 0 = no pain and 10 = worst possible pain, how much pain did you have while bending your knee?"

Secondary Outcome Measures :
  1. Number of Participants With Adverse Events or Serious Adverse Events Through 30 Days [ Time Frame: Up to 30 days ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 75 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Male or female, greater than or equal to 18 and less than or equal to 75 years of age at the Screening Visit.
  2. Female subjects only: Postmenopausal, surgically sterile, or willing to use acceptable means of contraception for at least 30 days after surgery including any of the following: hormonal contraceptives (e.g., oral, injectable, implantable starting at least 30 days before study drug administration), effective double-barrier methods (e.g., condoms with spermicide), intrauterine device, lifestyle with a personal choice of abstinence, nonheterosexual lifestyle, or a strictly monogamous relationship with a partner who has had a vasectomy.
  3. Scheduled to undergo primary unilateral total knee arthroplasty (TKA) under general anesthesia.
  4. American Society of Anesthesiology (ASA) Physical Class 1-3.
  5. Able and willing to comply with all study visits and procedures.
  6. Able to speak, read, and understand the language of the Informed Consent, study questionnaires, and other instruments used for collecting subject-reported outcomes, in order to enable accurate and appropriate responses to pain scales and other required study assessments.
  7. Willing and capable of providing written informed consent.

Exclusion Criteria:

  1. Pregnancy, nursing, or planning to become pregnant during the study or within one month after dosing.
  2. Use of any of the following medications within the times specified before surgery:

    • Long-acting opioid medication within 3 days.
    • Any opioid medication within 24 hours.
  3. Concurrent, painful, physical condition or concurrent surgery that may require analgesic treatment in the postoperative period for pain that is not strictly related to the surgical site administered study treatment, and which may confound the postoperative assessments (e.g., significant pain from other joints, chronic neuropathic pain, concurrent contralateral TKA, concurrent foot surgery, etc.).
  4. Body weight less than 50 kilograms (110 pounds) or morbid obesity.
  5. Contraindication to any of the pain-control agents planned for postoperative use (e.g., acetaminophen, morphine, oxycodone, ketorolac).
  6. Contraindication to epinephrine, such as concurrent administration of monoamine oxidase (MAO) inhibitors or antidepressants of amitriptyline or imipramine types, conditions where the production or exacerbation of tachycardia could prove fatal (e.g., poorly controlled thyrotoxicosis or severe heart disease), or any other pathological conditions that might be aggravated by the effects of epinephrine.
  7. Administration of an investigational drug within 30 days or 5 elimination half-lives of such investigational drug, whichever is longer, prior to study drug administration, or planned administration of another investigational product or procedure during the subject's participation in this study.
  8. History of, suspected, or known addiction to or abuse of illicit drug(s), prescription medicine(s), or alcohol within the past 2 years.
  9. Uncontrolled anxiety, schizophrenia, or other psychiatric disorder that, in the opinion of the Investigator, may interfere with study assessments or compliance.
  10. Current or historical evidence of any clinically significant disease or condition, especially cardiovascular or neurological conditions that, in the opinion of the Investigator, may increase the risk of surgery or complicate the subject's postoperative course.
  11. Significant medical conditions or laboratory results that, in the opinion of the Investigator, indicate an increased vulnerability to study drugs and procedures, and expose the subject to an unreasonable risk as a result of participating in this clinical trial, such as: debilitating diseases, acute illnesses, hypotension, partial or complete conduction block, impaired cardiac function, untreated hypertension, advanced arteriosclerotic heart disease, cerebral vascular insufficiency, pre-existing abnormal neurological or neuromuscular disease (e.g., epilepsy, myasthenia gravis), advanced liver disease, severe renal impairment, advanced diabetes comorbid conditions associated with an immunocompromised status, such as blood dyscrasias, HIV/AIDS, or recent chemotherapy.

    In addition, the subject will be ineligible to receive study drug if he or she meets the following criteria during surgery:

  12. Any clinically significant event or condition uncovered during surgery(e.g., excessive bleeding), which occurs before study drug administration, that might render the subject medically unstable or complicate the subject's postoperative course.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00485693

Layout table for location information
United States, Alabama
West Alabama Research, Inc.
Birmingham, Alabama, United States, 35209
United States, California
California Clinical Research, Inc.
Davis, California, United States, 95616
Accurate Clinical Trials, Inc.
Laguna Hills, California, United States, 92653
United States, New York
St. Luke's Roosevelt Hospital
New York, New York, United States, 10019
United States, Ohio
The Ohio State University Medical Center
Columbus, Ohio, United States, 43220
United States, Texas
Texas Tech University Health Science Center
Lubbock, Texas, United States, 79430
Urazova Nemocnice Brno
Brno, Czechia, 66250
Regional Hospital Kladno
Kladno, Czechia, 1548
The Hospital Trebic
Třebíč, Czechia, 67401
Sponsors and Collaborators
Pacira Pharmaceuticals, Inc
Layout table for investigator information
Study Director: Joyce Davis, RN Pacira Pharmaceuticals, Inc
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Layout table for additonal information
Responsible Party: Pacira Pharmaceuticals, Inc
ClinicalTrials.gov Identifier: NCT00485693    
Other Study ID Numbers: SKY0402C208
First Posted: June 13, 2007    Key Record Dates
Results First Posted: August 6, 2013
Last Update Posted: June 28, 2022
Last Verified: June 2022
Keywords provided by Pacira Pharmaceuticals, Inc:
total knee arthroplasty
Additional relevant MeSH terms:
Layout table for MeSH terms
Pain, Postoperative
Postoperative Complications
Pathologic Processes
Neurologic Manifestations
Anesthetics, Local
Central Nervous System Depressants
Physiological Effects of Drugs
Sensory System Agents
Peripheral Nervous System Agents
Adrenergic alpha-Agonists
Adrenergic Agonists
Adrenergic Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Adrenergic beta-Agonists
Bronchodilator Agents
Autonomic Agents
Anti-Asthmatic Agents
Respiratory System Agents
Vasoconstrictor Agents